A major obstacle to research in pancreatic cancer has been lack of access to high-quality annotated specimens of human tissues from all stages of PDAC. This difficulty is due to the relative inaccessibility of the pancreas and its prominent fibrous component, which make it technically difficult to obtain samples of sufficient heoplastic cellularity for many analytic approaches. The overall goal of the BioBank Core will be established to assist PPG member laboratories in the accrual and centralization of biologic resources that are critically required for pancreatic cancer research.
Specific aims are directed at: 1) maintaining a centralized, molecularly annotated human-derived murine xenograft core which'can enrich and amplify the neoplastic cell population while maintaining the genotypic and histologic character closest to that of the parent human cancer;2) providing a molecularly annotated cell-line repository. To accomplish these aims we will take advantage of our immediate access to human surgical specimens and mouse tumors to provide P01 investigators with biological materials that have been subjected to extensive characterization at the histologic and genetic levels (in collaboration with the Experimental Pathology Core). These materials include: serially passaged xenografts created from human pancreatic cancer specimens from primary and metastatic cancers;PDAC cell lines from our mouse models with varying tumor suppressor gene mutations; and primary mouse pancreatic ductal cells with various mutational profiles. Together, these resources should provide standardized cellular systems to facilitate experimental studies. The Core also maintains a repository of nearly all available PDAC cell lines;these have been subjected to high-resolution CGH and expression profiling, enabling investigators to retrieve needed cell lines with an appropriate genomic profile. The Core will interact closely with the Projects of the P01 to provide the biological materials and aid in the design and interpretation of experiments employing the xenografts and primary cells. The Core will seek to ensure a high level of quality control of specimens and standardization of protocols to ensure the effective translation of results between P01 Projects.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA117969-04
Application #
7754682
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-01-01
Budget End
2009-12-31
Support Year
4
Fiscal Year
2009
Total Cost
$135,612
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Lundquist, Mark R; Goncalves, Marcus D; Loughran, Ryan M et al. (2018) Phosphatidylinositol-5-Phosphate 4-Kinases Regulate Cellular Lipid Metabolism By Facilitating Autophagy. Mol Cell 70:531-544.e9
Hopkins, Benjamin D; Pauli, Chantal; Du, Xing et al. (2018) Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature 560:499-503
Biancur, Douglas E; Kimmelman, Alec C (2018) The plasticity of pancreatic cancer metabolism in tumor progression and therapeutic resistance. Biochim Biophys Acta Rev Cancer 1870:67-75
Chen, Yang; LeBleu, Valerie S; Carstens, Julienne L et al. (2018) Dual reporter genetic mouse models of pancreatic cancer identify an epithelial-to-mesenchymal transition-independent metastasis program. EMBO Mol Med 10:
Hill, Margaret A; Alexander, William B; Guo, Bing et al. (2018) Kras and Tp53 Mutations Cause Cholangiocyte- and Hepatocyte-Derived Cholangiocarcinoma. Cancer Res 78:4445-4451
Mendt, Mayela; Kamerkar, Sushrut; Sugimoto, Hikaru et al. (2018) Generation and testing of clinical-grade exosomes for pancreatic cancer. JCI Insight 3:
Patra, Krushna C; Kato, Yasutaka; Mizukami, Yusuke et al. (2018) Mutant GNAS drives pancreatic tumourigenesis by inducing PKA-mediated SIK suppression and reprogramming lipid metabolism. Nat Cell Biol 20:811-822
Anglin, Justin; Zavareh, Reza Beheshti; Sander, Philipp N et al. (2018) Discovery and optimization of aspartate aminotransferase 1 inhibitors to target redox balance in pancreatic ductal adenocarcinoma. Bioorg Med Chem Lett 28:2675-2678
Yang, Annan; Herter-Sprie, Grit; Zhang, Haikuo et al. (2018) Autophagy Sustains Pancreatic Cancer Growth through Both Cell-Autonomous and Nonautonomous Mechanisms. Cancer Discov 8:276-287
Santana-Codina, Naiara; Roeth, Anjali A; Zhang, Yi et al. (2018) Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis. Nat Commun 9:4945

Showing the most recent 10 out of 134 publications